Efinopegdutide Drug Asset Due Diligence Report 2026

This Efinopegdutide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Efinopegdutide can convert its Fusion protein profile and GCGR x GLP-1R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Efinopegdutide (query alias: efinopegdutide)
Modality / target	Fusion protein; GCGR x GLP-1R; GCGR agonists, GLP-1R agonists
Highest global status	Phase 2
Originator	Hanmi Pharmaceutical Co., Ltd.
Active developers	Hanmi Pharmaceutical Co., Ltd., Merck Sharp & Dohme LLC

The MCP disease footprint includes Liver Cirrhosis, Metabolic Dysfunction Associated Steatohepatitis, Obesity. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06482112	Phase 2	Completed	124	Mean Relative Reduction From Baseline in Liver Fat Content at Week 28
CTR20233311	Phase 2	已完成	17	Not disclosed
NCT06701305	Phase 1	Completed	48	Part 1: Number of Participants Who Experience an Adverse Event (AE)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 2a Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Different Dosing Regimens of Efinopegdutide (MK-6024) in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease

Phase 2; n=124; evaluation: not stated. Reported fields: Mean Relative Reduction From Baseline in Liver Fat Content at Week 28(Least Squares Mean) = 67.8 Percent Reduction (90% Confidence Interval, 60.7 - 74.9); Mean Relative Reduction From Baseline in Liver Fat Content at Week 28(Least Squares Mean) = 42.1 Percent Reduction (90% Confidence Interval, 34.6 - 49.5); -

An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Efinopegdutide (MK-6024) in Participants With Moderate and Severe Hepatic Impairment

Phase 1; n=22; evaluation: not stated. Reported fields: Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Efinopegdutide(Geometric Mean) = 146 hr*μg/mL (95% Confidence Interval, 81.8 - 262); Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Efinopegdutide(Geometric Mean): Geometric Mean Ratio = 0.97(90% CI, 0.61 - 1.54); Geometric Mean Ratio = 1.04(90% CI, 0.63 - 1.71); Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Efinopegdutide(Geometric Mean) = 152 hr*μg/mL (95% Confidence Interval, 106 - 219)

A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease

Phase 2; n=145; evaluation: not stated. Reported fields: Mean Relative Reduction From Baseline in Liver Fat Content (LFC) Measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF), Evaluated by Blinded Independent Central Review (BICR) After 24 Weeks(Least Squares Mean) = 42.3 Percent Reduction (90% Confidence Interval, 36.5 - 48.1); Mean Relative Reduction From Baseline in Liver Fat Content (LFC) Measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF), Evaluated by Blinded Independent Central Review (BICR) After 24 Weeks(Least Squares Mean) = 72.7 Percent Reduction (90% Confidence Interval, 66.8 - 78.7); Mean Relative Reduction From Baseline in Liver Fat Content (LFC) Measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF), Evaluated by Blinded Independent Central Review (BICR) After 24 Weeks(Least Squares Mean): Difference in least squared means = 30.4(90% CI, 22.1 - 38.7), P-Value = <0.0001

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Efinopegdutide addresses Liver Cirrhosis, Metabolic Dysfunction Associated Steatohepatitis, Obesity. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Fusion protein—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2020-08-04	Merck partners with Hanmi to develop and market efinopegdutide for NASH globally, including the US.	Phase 2	US$10.0M upfront; US$860.0M milestones; US$870.0M stated total
2019-07-08	J&J dumps Hanmi obesity drug following midphase trials	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “GLP-1 receptor agonist compounds for treating a proliferative synovial disorder”. The milestone feed surfaced a patent-application signal described as “Composition comprising a GLP1r agonist and engineered extracellular vesicles comprising adiponectin, and uses thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO